[Experience with cefuroxime in pediatric field (author's transl)]
Related Experiment Videos
Abstract:
Having resistance to beta-lactamase-producing strains and showing resistance to not only cephalosporin resistant strains of E. coli and Klebsiella but also to Citrobacter, Proteus and Enterobacter, Cefuroxime (CXM) was used in pediatric field for both fundamental and clinical studies. CXM was found to be a useful antibiotic in views of high clinical efficacy rate obtained and no side effect noted. As for the dose, the single dose of 25 mg/kg achieved sufficient blood levels. Also in view of good clinical effect, the dose of 25 mg/kg three or four times daily seems appropriate for treatment of children.
Insights
Cefuroxime (CXM) demonstrates effectiveness against resistant bacteria like E. coli and Klebsiella in children. Clinical studies show high efficacy and no side effects, with a recommended pediatric dose of 25 mg/kg.
Area of Science:
- Pediatric infectious diseases
- Antibiotic efficacy studies
- Pharmacokinetics in children
Background:
- Beta-lactamase-producing bacteria pose a significant challenge in pediatric infections.
- Cephalosporin resistance in common pediatric pathogens like E. coli and Klebsiella necessitates alternative treatments.
- Emerging resistance in Citrobacter, Proteus, and Enterobacter species further complicates treatment options.